Combinations for cancer prevention

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 974-975

  Gupta, Rajnish A ^a   DuBois, Raymond N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EKB 569; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GROWTH INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; UNCLASSIFIED DRUG;

ADENOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI; ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; MICE; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULINDAC;

EID: 0033835321     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79664     Document Type: Article

References (11)

1. Torrance, et al. Combinatorial chemoprevention of intestinal neoplasia using an NSAID and an EGFR-kinase inhibitor. Nature Med. 6, 1024-1028 (2000).
2. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
3. Pegram, M. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671 (1998).
4. Kelloff, G. et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 5, 657-666 (1996).
5. Masferrer, J.L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 Inhibitors. Cancer Res. 60, 1306-1311 (2000).
6. Tsujii, M. et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716 (1998).
7. Williams, C.S., Tsujii, M., Reese, J., Dey, S.K. & DuBois, R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589-1594 (2000).
8. He, T.C., Chan, T.A., Vogelstein, B. & Kinzler, K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335-345 (1999).
9. Feldman, A.M., Lorell, B.H. & Reis, S.E. Trastuzumab in the treatment of metastatic breast cancer: anti-cancer therapy versus cardiotoxicity. Circulation 102, 272-274 (2000).
10. Laine, L. et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117, 776-783 (1999).
11. Simon, L.S. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J. Am. Med. Assoc. 282, 1921-1928 (1999).